Morgan Stanley
KRRO icon

Morgan Stanley’s Korro Bio KRRO Stock Holding History

Morgan Stanley’s Portfolio KRRO Stock Details KRRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$297K Sell
22,501
-18,622
-45% -$231K ﹤0.01% 5780
2026
Q1 		$466K Sell
41,123
-28,605
-41% -$315K ﹤0.01% 5522
2025
Q4 		$559K Sell
69,728
-97,766
-58% -$2.29M ﹤0.01% 5450
2025
Q3 		$8.02M Buy
167,494
+85,761
+105% +$1.9M ﹤0.01% 3739
2025
Q2 		$1.02M Buy
81,733
+38,633
+90% +$556K ﹤0.01% 5089
2025
Q1 		$750K Buy
43,100
+14,538
+51% +$431K ﹤0.01% 5139
2024
Q4 		$1.09M Buy
28,562
+5,207
+22% +$268K ﹤0.01% 5043
2024
Q3 		$781K Buy
23,355
+10,334
+79% +$435K ﹤0.01% 5181
2024
Q2 		$441K Buy
13,021
+5,352
+70% +$296K ﹤0.01% 5346
2024
Q1 		$690K Buy
7,669
+1,701
+29% +$92.8K ﹤0.01% 5161
2023
Q4 		$286K Buy
5,968
+5,264
+748% +$173K ﹤0.01% 5564
2023
Q3 		$13K Buy
704
+620
+738% +$15.6K ﹤0.01% 6632
2023
Q2 		$1.46K Sell
84
-1,648
-95% -$32K ﹤0.01% 7241
2023
Q1 		$43.6K Buy
1,732
+1,280
+283% +$146K ﹤0.01% 6333
2022
Q4 		$87K Sell
452
-148
-25% -$15.2K ﹤0.01% 6047
2022
Q3 		$54K Sell
600
-718
-54% -$72.9K ﹤0.01% 6372
2022
Q2 		$99K Buy
1,318
+279
+27% +$18.9K ﹤0.01% 6281
2022
Q1 		$110K Sell
1,039
-2,969
-74% -$567K ﹤0.01% 6247
2021
Q4 		$1.03M Sell
4,008
-6,568
-62% -$2M ﹤0.01% 5048
2021
Q3 		$3.73M Sell
10,576
-3,710
-26% -$1.46M ﹤0.01% 4025
2021
Q2 		$7.12M Buy
14,286
+14,015
+5,172% +$6.84M ﹤0.01% 3395
2021
Q1 		$129K Sell
271
-7,796
-97% -$15.1M ﹤0.01% 5881
2020
Q4 		$14.2M Buy
8,067
+7,834
+3,362% +$10.3M ﹤0.01% 2157
2020
Q3 		$225K Sell
233
-1,380
-86% -$1.48M ﹤0.01% 5044
2020
Q2 		$1.88M Buy
1,613
+1,516
+1,563% +$1.37M ﹤0.01% 3658
2020
Q1 		$86K Sell
97
-168
-63% -$181K ﹤0.01% 5244
2019
Q4 		$232K Buy
+265
New +$206K ﹤0.01% 5355

Other funds holding KRRO

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Morgan Stanley's KRRO Position: Q2 2026 in Review

Morgan Stanley reduced its Korro Bio (KRRO) stake by 45% in Q2 2026, selling an estimated $231K and leaving 22,501 shares worth $297K. The position accounts for ﹤0.01% of the portfolio, ranked #5780.

Morgan Stanley first reported a position in KRRO in Q4 2019 and has held it in 27 quarters since. The position peaked at $14.2M in Q4 2020. 106 funds tracked by Wall St. Rank hold KRRO as of Q2 2026.

  • Morgan Stanley held 22,501 shares of Korro Bio worth $297K as of Q2 2026.
  • Morgan Stanley sold 18,622 Korro Bio shares in Q2 2026, an estimated $231K.
  • Korro Bio made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #5780 holding.
  • Morgan Stanley first reported a position in Korro Bio in Q4 2019 and has held it in 27 quarters since.
  • Morgan Stanley's Korro Bio position peaked at $14.2M in Q4 2020.
  • 106 funds tracked by Wall St. Rank held Korro Bio as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.